METROPOLIS - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 3.4
| Stock Code | METROPOLIS | Market Cap | 9,728 Cr. | Current Price | 1,876 ₹ | High / Low | 2,263 ₹ |
| Stock P/E | 67.5 | Book Value | 256 ₹ | Dividend Yield | 0.05 % | ROCE | 13.4 % |
| ROE | 10.5 % | Face Value | 2.00 ₹ | DMA 50 | 1,886 ₹ | DMA 200 | 1,912 ₹ |
| Chg in FII Hold | -0.84 % | Chg in DII Hold | 1.63 % | PAT Qtr | 38.0 Cr. | PAT Prev Qtr | 46.6 Cr. |
| RSI | 50.4 | MACD | -19.7 | Volume | 85,273 | Avg Vol 1Wk | 79,508 |
| Low price | 1,315 ₹ | High price | 2,263 ₹ | PEG Ratio | -4.83 | Debt to equity | 0.11 |
| 52w Index | 59.2 % | Qtr Profit Var | 38.9 % | EPS | 26.6 ₹ | Industry PE | 32.6 |
📊 Financial Overview
- Revenue & Profitability: PAT declined from 46.6 Cr. to 38.0 Cr. QoQ, showing weakness. EPS at 26.6 ₹ is modest relative to valuation.
- Margins & Returns: ROE at 10.5% and ROCE at 13.4% are moderate, reflecting average capital efficiency.
- Debt & Liquidity: Debt-to-equity ratio of 0.11 indicates low leverage, enhancing financial stability.
- Cash Flow: Profitability supports reinvestment, but margins remain under pressure.
💹 Valuation Metrics
- P/E Ratio: 67.5 vs Industry PE of 32.6 → Highly overvalued.
- P/B Ratio: ~7.3 (Price 1,876 ₹ / Book Value 256 ₹) → Expensive relative to assets.
- PEG Ratio: -4.83 → Negative, indicating unsustainable growth expectations.
- Intrinsic Value: Current price appears significantly above fair value zone.
🏢 Business Model & Competitive Advantage
Metropolis Healthcare operates in diagnostic services, with a strong presence in pathology and testing. Its brand recognition and wide network provide a competitive edge. However, profitability pressures and stretched valuations limit near-term attractiveness.
📈 Entry Zone & Long-Term Guidance
Technically, RSI at 50.4 and negative MACD suggest weakness. A better entry zone would be 1,750–1,800 ₹ (near support levels). Long-term holding is advisable only if earnings growth stabilizes and valuations normalize.
✅ Positive
- Low debt-to-equity ratio (0.11).
- DII holdings increased (+1.63%), showing strong domestic confidence.
- Strong brand presence in diagnostics.
⚠️ Limitation
- High P/E (67.5) and P/B (~7.3) ratios.
- Negative PEG ratio (-4.83) indicates unsustainable growth pricing.
- Quarterly PAT decline (38 Cr. vs 46.6 Cr.).
📉 Company Negative News
- FII holdings decreased (-0.84%), showing reduced foreign confidence.
- Profitability weakened QoQ.
📈 Company Positive News
- DII accumulation (+1.63%) signals strong domestic support.
- Stable EPS at 26.6 ₹ despite profit decline.
🏭 Industry
The diagnostics industry benefits from rising healthcare demand, preventive testing, and lifestyle-related health checks. Industry PE at 32.6 highlights Metropolis Healthcare’s premium valuation relative to peers.
🔎 Conclusion
Metropolis Healthcare is fundamentally stable with strong brand presence and low debt, but valuations are stretched and profitability has weakened. While domestic investor confidence is a positive, foreign sentiment has declined. Accumulation near 1,750–1,800 ₹ is recommended only for long-term holding if earnings growth stabilizes and valuation multiples normalize.